Nct04223856 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nct04223856. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nct04223856 Today - Breaking & Trending Today

Enfortumab Vedotin Plus Pembrolizumab Generates Survival Benefit in Previously Untreated Advanced Urothelial Cancer

Treatment with the combination of enfortumab Vedotin and pembrolizumab led to an improvement in overall survival and progression-free survival compared with chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer who were eligible for cisplatin- or carboplatin-containing chemotherapy. ....

City Of , United Kingdom , Thomas Powles , Eliav Barr , Barts Cancer Center , Queen Mary University Of London , Merck Research Laboratories , Queen Mary University , Immunotherapy In Gu Cancers , Urothelial Cancer , Immuno Oncology , Enfortumab Vedotin , Keynote A39 Ev 302 Trial ,

Dr Gupta on Criteria for the EV-103 Trial in Advanced Urothelial Cancer

Shilpa Gupta, MD, discusses the enrollment criteria used for the phase 1/2 EV-103 trial in patients with locally advanced or metastatic urothelial carcinoma, and highlights next steps for the investigation of the frontline combination of enfortumab vedotin and pembrolizumab in the phase 3 EV-302 trial.
....

Shilpa Gupta , Taussig Cancer Institute , Genitourinary Oncology Program , Genitourinary Medical Oncology , Cleveland Clinic , Urothelial Cancer , Onclive Tv ,